|
|
|
Volumn 26, Issue 1 SUPPL. 5, 1999, Pages 1-5
|
|
Setting a new standard - Irinotecan (Campto) in the second-line therapy of colorectal cancer: Final results of two phase III studies and implications for clinical practice
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
DNA TOPOISOMERASE INHIBITOR;
FLUOROURACIL;
IRINOTECAN;
ANTINEOPLASTIC ACTIVITY;
CANCER SURVIVAL;
CLINICAL PRACTICE;
CLINICAL TRIAL;
COLORECTAL CANCER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG SCREENING;
HUMAN;
INFUSION;
MAJOR CLINICAL STUDY;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIAL;
REVIEW;
SURVIVAL RATE;
TREATMENT PLANNING;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
CAMPTOTHECIN;
CLINICAL TRIALS, PHASE III;
COLORECTAL NEOPLASMS;
DNA TOPOISOMERASES, TYPE I;
FLUOROURACIL;
HUMANS;
PALLIATIVE CARE;
RANDOMIZED CONTROLLED TRIALS;
|
|
EID: 0032965985
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (19)
|
|
References (29)
|
